Isotechnika partner invited to present on drug eluting stent trial using voclosporin



    EDMONTON, Oct. 16 /CNW/ - (ISA:TSX): Isotechnika Inc. today announced
that its medical device partner, Atrium Medical Corporation, presented new
data on its drug eluting coronary stent. Atrium presented the protocol design
for its CONFIRM 1 trial, a First-in-Man trial of its CINATRA(TM) product, a
drug eluting coronary stent coated with voclosporin. Atrium reported that the
trial has enrolled 69 of its targeted 100 patients at seven sites in Belgium,
and the Company expects to complete enrollment by the end of 2008. Data
collected thus far were presented at the 20th Annual Transcather
Cardiovascular Therapeutics (TCT) Conference held in Washington, DC from
October 12th to 17th. Isotechnika licensed voclosporin to Atrium Medical in
2005 for the exclusive use with implantable medical devices.
    "Atrium's CONFIRM 1 trial further validates the multiple applications of
our proprietary voclosporin compound. Voclosporin was selected by Atrium to be
combined with its CINATRA(TM) coronary stent system for its desirable
anti-inflammatory properties in the vascular system," said Dr. Robert Foster,
Chief Executive Officer of Isotechnika. "Atrium expects to file for CE mark
approval in the EU for CINATRA(TM) as early as the fourth quarter of 2010. The
worldwide market for these stents is estimated to be $4 billion."
    "Interventional cardiologists have been waiting for a new technology that
delivers the effectiveness of a drug eluting stent with a safer, more natural,
non-polymeric coating platform," said Trevor Carlton, President of Atrium
Medical Corporation. "By combining the benefits of our patented Omega 3
coating platform with Isotechnika's novel drug compound voclosporin,
CINATRA(TM) represents a novel treatment options for patients requiring a drug
eluting coronary stent. This combination has the potential to result in a
better healed implant shortly after implantation."
    CONFIRM 1 trial is a First-in-Man, prospective, multi-center, single
blind, randomized, controlled study using the CINATRA(TM) voclosporin coated
coronary stent system, which will be compared to Atrium's CINATRA(TM) bare
metal coronary stent (BMS) platform. The study will enroll 100 patients and
will be conducted at seven hospitals in Belgium with Glenn Van Langenhove, MD,
PhD of Middelheim Hospital, Antwerp, serving as the study's principal
investigator. The primary endpoint of the trial is to evaluate the safety and
performance of the CINATRA(TM) voclosporin coated coronary stent system
compared to the CINATRA BMS coronary stent system in patients with de novo
coronary artery disease. Patient outcomes, in addition to drug coated stent
performance, will be assessed by measuring Late Lumen Loss at six months
following implantation.
    As part of its presentation, Atrium also released preclinical data from a
porcine animal model demonstrating a reduction in inflammation in the CINATRA
arm for each of the three voclosporin dose groups relative to the other
control groups. A reduction in neointima was also observed, likely related to
inflammation reduction. No safety issues were observed in any dose group. For
additional information on the 20th Annual TCT conference please visit
http://www.tctconference.com/.

    About Isotechnika

    Edmonton-based Isotechnika Inc. is an international biopharmaceutical
company focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments. There is a significant unmet medical need in the
treatment of both solid organ transplantation and autoimmune disease. It is
estimated that the market potential will exceed $4 billion annually in sales
for calcineurin inhibitors such as voclosporin by 2010.
    Voclosporin is a next generation calcineurin inhibitor, which recently
completed a Phase 2b North American trial for the prevention of kidney
rejection following transplantation. An extension to the Phase 2b trial and a
combined Phase 3 European/Canadian trial for the treatment of moderate to
severe psoriasis are ongoing. Our partner, Lux Biosciences, is currently
conducting three separate Phase 2/3 pivotal trials investigating voclosporin
(referred to as LUVENIQTM by Lux) for the treatment of uveitis. Voclosporin
has also entered First-in-Man trials as the drug utilized in the CINATRA(TM)
Drug Coated Coronary Stent system developed by the Company's partner, Atrium
Medical Corporation.
    Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can be found
at www.isotechnika.com or www.SEDAR.com.

    Forward-Looking Statements

    This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the potential of its
products, the Company's expectations regarding the issuance of additional
patents and the Company's ability to protect its intellectual property,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward
looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its products, the
ability of the Company to defend its patents from infringement by third
parties, and the risk that the Company's patents may be subsequently shown to
be invalid or infringe the patents of others. Investors should consult the
Company's quarterly and annual filings with the Canadian commissions for
additional information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements.

    %SEDAR: 00010508E




For further information:

For further information: Stephanie Gillis-Paulgaard, Director, Corporate
Communications, Isotechnika Inc., Phone: (780) 909-4661, Fax: (780) 484-4105,
E-mail: sgillis-paulgaard@isotechnika.com

Organization Profile

ISOTECHNIKA PHARMA INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890